GM-CSF-secreting vaccines for solid tumors: moving forward.

Richa Gupta, Leisha A. Emens

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer vaccines consisting of intact tumor cells genetically modified to secrete the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) have undergone extensive preclinical development. These vaccines induce the massive accumulation of dendritic cells at the intradermal injection site, which engulf, process, and present tumor antigens to activate tumor-specific T cells. Early phase clinical testing demonstrated promising evidence of safety and bioactivity, although initial phase III clinical trials were unsuccessful. Together, the preclinical and clinical data argue for the continued clinical development of these vaccines, integrating them with standard and novel cancer therapeutics that enhance vaccine activity by overcoming immune tolerance and suppression, and/or augmenting co-stimulatory pathways of T cell activation.

Original languageEnglish (US)
Pages (from-to)52-60
Number of pages9
JournalDiscovery Medicine
Volume10
Issue number50
StatePublished - Jul 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'GM-CSF-secreting vaccines for solid tumors: moving forward.'. Together they form a unique fingerprint.

Cite this